Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) posted its earnings results on Monday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.13), FiscalAI reports. The business had revenue of $5.65 million during the quarter, compared to analysts’ expectations of $29.00 million.
Prelude Therapeutics Stock Down 2.6%
NASDAQ:PRLD opened at $3.32 on Wednesday. Prelude Therapeutics has a twelve month low of $1.29 and a twelve month high of $6.83. The business has a 50 day moving average price of $3.92 and a two-hundred day moving average price of $4.08. The company has a market cap of $264.94 million, a P/E ratio of -5.63 and a beta of 1.22.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on PRLD shares. Citigroup reiterated a “market outperform” rating on shares of Prelude Therapeutics in a report on Wednesday, October 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Prelude Therapeutics in a research note on Tuesday, October 27th. Wall Street Zen downgraded shares of Prelude Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, September 19th. JPMorgan Chase & Co. began coverage on shares of Prelude Therapeutics in a research note on Thursday, September 17th. They issued an “overweight” rating and a $12.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Prelude Therapeutics in a research report on Wednesday. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.
View Our Latest Stock Report on Prelude Therapeutics
Prelude Therapeutics Company Profile
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival. Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.
Read More
- Five stocks we like better than Prelude Therapeutics
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
